首选化放疗或手术治疗喉癌疗效的系统评价

    Systematic Overview of Primary Management of Laryngeal Cancer by Chemoradiotherapy or Surgery

    • 摘要: 目的 系统评价首选化放疗或手术治疗喉癌患者生存率和生活质量。 方法 全面检索MEDLINE(1953年至2013年3月)、Cochrane 图书馆、CBMdisc(1953年至2013年3月)以及截至2013年3月的中文全文数据库(VIP、CNKI等),对符合纳入标准的临床对照试验,采用RevMan 4.3软件进行Meta分析。结果纳入10个临床对照研究,包含病例数2 356例。Meta分析结果表明,首选化放疗或手术治疗喉癌总生存率的差异没有统计学意义(P=0.06),合并比值比及其95%可信区间为0.87(0.72,1.06);而首选化放疗治疗喉癌的喉功能保留率显著高于手术组(P=0.006),合并比值比及其95%可信区间为0.23(0.12,0.44)。 结论 首选化放疗治疗喉癌与手术的总生存率相同,而喉功能保留率高于手术组。早期喉癌患者首选化放疗可更好保留喉功能,喉切除术可作为失败后的挽救治疗手段。

       

      Abstract: Objective To evaluate the survival rate and quality of life after primary management of laryngeal cancer by chemoradiotherapy or surgery. Methods We searched the MEDLINE, Cochrane Library, CBMdisc and some Chinese journals. Controlled clinical trials meeting the selection criteria were eligible. Meta-analysis was done using the Cochrane collaboration’s RevMan 4.3. Results Ten controlled clinical trials were included. According to the meta-analysis, there were no statistical differences in survival rate between chemoradiotherapy group and surgery groupOR=0.87, 95%CI (0.72,1.06), P=0.06. Larynx preservation treated by chemoradiotherapy was significantly higher than surgery groupOR=0.23, 95%CI (0.12,0.44), P=0.006. Conclusions Primary chemoradiatiotherapy achieved equivalent Results of survival rate, higher larynx preservation, and probably higher quality of life as compared to surgery. Treatment option was chemoradiotherapy with surgery for salvage of radiotherapeutic failure.

       

    /

    返回文章
    返回